Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that St. Bonifatius Hospital in Lingen, Germany is celebrating five years of delivering advanced stereotactic radiosurgery (SRS) using the ZAP-X® Gyroscopic Radiosurgery® platform – marking a major milestone in expanding access to elite brain tumor care beyond major metropolitan centers. Following a steady yet ambitious ramp-up, annual patient volume has now su...

PRINCETON, N.J. & ESPOO, Finland--(BUSINESS WIRE)--IQM Finland Oy, a global leader in deployed on-premises, full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp., a special purpose acquisition company (Nasdaq: RAAQ) (“RAAQ”), today announced the confidential submission of the draft registration statement on Form F-4 (the “Registration Statement”) filed by IQM with the U.S. Securities and Exchange Commission (“SEC”) relat...

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Sovato appoints industry veteran and former Intuitive executive Brian Miller, PhD, as CEO to scale its remote surgery and procedure platform....

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls...

SALT LAKE CITY--(BUSINESS WIRE)--ReposiTrak (NYSE:TRAK), the world’s largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, announces the addition of eighteen fresh fruit and vegetable companies to the queue for the ReposiTrak Traceability Network®. By joining the queue now, these companies are taking the first critical step toward efficiently exchanging FDA-required Key Data Elements (KDEs) for each...

VODNJAN, Croatia--(BUSINESS WIRE)--Global AI-first cloud communications platform Infobip partnered with Telescope, the leader in real-time audience engagement, to deploy multiple fan engagement campaigns, including processing fan voting for American Idol, the Brit Awards and recent BAFTA Awards. With their reach and availability on all mobile phones around the world, SMS and WhatsApp are a part of the most reliable messaging services and are a staple platform for businesses’ communication strat...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation of Parkinsonian syndromes. neuropacs™ is the first medical device classified by the FDA under the new category of “Parkinsonian syndrome diagnostic aid.” The software analyzes diffusion MRI data t...

SAN FRANCISCO--(BUSINESS WIRE)--Alphy, the company behind HarmCheck, announced today that investor Monica Alvarez-Mitchell and Radicle Impact co-founder Dan Skaff have joined its board of directors, marking another step forward for the fast-rising AI company as it expands across financial services, legal, and other highly regulated markets. The appointments follow a strategic investment from Alvarez-Mitchell and additional backing from Radicle Impact as demand accelerates for AI that can detect...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21...